CN100471508C - Medicine for treating cardiac and cerebral vascular diseases and its prepn process - Google Patents
Medicine for treating cardiac and cerebral vascular diseases and its prepn process Download PDFInfo
- Publication number
- CN100471508C CN100471508C CNB2005100566320A CN200510056632A CN100471508C CN 100471508 C CN100471508 C CN 100471508C CN B2005100566320 A CNB2005100566320 A CN B2005100566320A CN 200510056632 A CN200510056632 A CN 200510056632A CN 100471508 C CN100471508 C CN 100471508C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- cerebral vascular
- pheretima
- salviae miltiorrhizae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The medicine for treating cardiac and cerebral vascular diseases contains astragalus root, red sage, angelica, Chuanxiong rhizome, red peony root, safflower and earthworm. During the preparation process of the medicine, the said Chinese medicinal materials are soaked in water and decocted, the decoction is concentrated and alcohol precipitated before the alcohol is eliminated to produce the oral liquid. The medicine can dilate blood vessel, inhibit platelet aggregation, dissolve thrombus, eliminate atherosclerosis clot, lower blood fat and serum cholesterol and improve cardiac and cerebral vascular circulation. It can cure cardiac and cerebral vascular diseases radically and has high curative effect and less toxic side effect.
Description
One, technical field
The present invention relates to a kind of medicine for the treatment of cardiovascular and cerebrovascular disease, specifically a kind of is the medicine of feedstock production with the Chinese herbal medicine, the invention still further relates to the preparation method of this medicine.
Two, background technology
Cardiovascular and cerebrovascular disease is meant diseases such as arteriosclerosis, apoplexy sequela and hypertension, hyperlipidemia, angina pectoris, it is one of frequently-occurring disease clinically, during pilosity is born in, the old people, the traditional Chinese medical science thinks that its pathogenesis is because venation block, healthy energy is lost empty, muscle arteries and veins muscle loses foster and causes blood stagnancy due to deficiency of QI, hemiplegia, the disease of slobbering.The morbidity of the heart, cerebrovascular disease is anxious, development is fast, disability rate is high, and harm is big, and the treatment difficulty is also big.To the treatment of cardiovascular and cerebrovascular disease, doctor trained in Western medicine generally adopts operation associating western medicine, has the misery on the health at present; And the traditional Chinese medical science adopts conservative Chinese medicine decoction mostly, and cure rate is low, and therapeutic effect is not obvious.
Three, summary of the invention
The objective of the invention is to overcome the deficiency of prior art, provide a kind of good effect, adaptability is strong, toxic and side effects is little, the treatment heart for the treatment of both the principal and secondary aspects of a disease, the medicine of cerebrovascular disease.
Another object of the present invention provides the preparation method of the medicine of this treatment heart, cerebrovascular disease.
The present invention treats in the medicine of the heart, cerebrovascular disease and contains the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Flos Carthami and Pheretima, and the weight proportion of wherein said each composition is:
The Radix Astragali 550-650g Radix Salviae Miltiorrhizae 550-650g
Radix Angelicae Sinensis 275-325g Rhizoma Chuanxiong 140-160g
Radix Paeoniae Rubra 200-250g Flos Carthami 140-160g
Pheretima 140-160g
The optimum weight proportioning of pharmaceutical compositions of the present invention is:
Radix Astragali 600g Radix Salviae Miltiorrhizae 600g
Radix Angelicae Sinensis 300g Rhizoma Chuanxiong 150g
Radix Paeoniae Rubra 225g Flos Carthami 150g
Pheretima 150g
The preparation method that the present invention treats the heart, cerebrovascular disease medicament is: get the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Flos Carthami and Pheretima Chinese crude drug, the water logging that adds 6 times of amounts was steeped 1 hour, then, decoct 2 times, each 1.5 hours, merge decoction liquor, be concentrated into 1: 2 (g/ml), add ethanol precipitation 2 times, make to contain alcohol amount and reach 75%, reclaim ethanol, be concentrated into and do not have the alcohol flavor, add water to the about 1000ml of solution total amount again, add an amount of stevioside then, transfer PH to 6.0-7.5 with 40%NaOH, placed 24 hours, filter sterilization, quantitative package.
The property of medicine of the various medicines of pharmaceutical formulation of the present invention: the Radix Astragali mainly contains water soluble polysaccharide, Radix Astragali glucose, astragaloside and several amino acids; Radix Salviae Miltiorrhizae mainly contains Radix Salviae Miltiorrhizae quinone, danshensu and original pair tea phenol etc., has certain acidity, water soluble; Rhizoma Chuanxiong, main component are lactone, alkaloids and phenolic compound, and be all water-soluble; Radix Paeoniae Rubra, contained Radix Paeoniae Rubra glucoside is also water-soluble, so make solvent with water, uses the decoction and alcohol sedimentation technique effective component extracting.The present invention share Qi-tonifying drug and blood circulation promoting medicine, with Radix Astragali strongly invigorating primordial QI, makes gas prosperous capable with short blood, and helping the masterpiece of all medicines is monarch drug, makes blood stasis dispelling and does not just hinder; With the Radix Salviae Miltiorrhizae blood stasis dispelling, to invigorate blood circulation be ministerial drug; Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Flos Carthami blood circulation promoting and blood stasis dispelling, Pheretima promoting blood circulation to remove obstruction in the collateral are adjuvant drug, and with the disease plus-minus, then healthy energy is strong to be used for disease, and blood stasis is dispelled, the venation tonneau, and all diseases can be healed.
The advantage that clinical drug of the present invention uses is: (1) blood vessel dilating, increase the heart, cerebral blood flow, and improve the heart, cerebral blood circulation, resist and improve the cerebrovascular anoxia; (2) microcirculation improvement; (3) improve hemorheological property, reduce blood viscosity, suppress platelet aggregation, artery thrombosis is obstructed; (4) can send out again with pre-preventing thrombosis by thrombus, remove atheromatous plaque; The revascularization that fundus observation can make thrombosis stop up; (5) blood fat reducing and serum cholesterol speed up erythrocyte electrophoresis.
In order to prove the therapeutic efficiency of medicine of the present invention, the present invention selects acute ischemic cerebrovascular disease people 134 examples as the object of observation from the inpatient at random, wherein select the 72 examples group of doing experiment at random, select 62 examples else and do matched group, give birth to arteries and veins, aspirin is made conventional therapy simultaneously.
Test group: male 44 examples, women 28 examples, average age of onset 60.5 years old.Matched group: male 38 examples, women 24 examples, average age of onset 64.1 years old.
1, case history choice criteria:
A. all case history all meets the 4th standards of grading that the cerebrovascular meeting is passed through in the nineteen ninety-five whole nation.
B. all cases all have head CT or MRI data, and diagnosis of cerebral infarction is clear and definite, and are fresh focus.
C. two groups of cases all are entocranial artery system infarction.
2, Therapeutic Method
Test group: add quiet of 0.9% sodium chloride 500ml with giving birth to arteries and veins 50ml, continuous 10-14 days once a day, oral the present invention obeyed liquid 10ml, 3 times/day, is aided with oral 1 time/evening of aspirin 80mg;
Matched group: add quiet of 0.9% sodium chloride 500ml with giving birth to arteries and veins 50ml, continuous 10-14 days once a day, add with oral SONGLING XUEMAIKANG 1g, 3 times/day, be aided with oral 1 time/evening of aspirin 80mg.
3, curative effect determinate standard: use the 4th efficacy assessment standard that the cerebrovascular academic conference is passed through in the nineteen ninety-five whole nation, preceding and treatment back scoring respectively at treatment:
The basic healing: the functional impairment scoring reduces 91%-100%, and invalid degree is 0 grade.
Marked improvement: the functional impairment scoring reduces 46%-90%, and invalid degree is the 1-3 level.
Progressive: the functional impairment scoring reduces 18%-45%.
No change: the functional impairment scoring reduces 17%.
The viability state that the patient is total: 0 grade: can resume work or manage household affairs, or return to the preceding state of disease.1 grade: take care of oneself, live on one's own life, partly work.2 grades: live on one's own life substantially, part needs the people to help.3 grades: the part viability can be taken care of oneself, and most of people of need helps.4 grades: the walking of can standing, but need the people to take care of at any time.5 grades: bed, can sit, every life needs the people to take care of.6 grades: bed, the part conscious activity is arranged, can feed.7 grades; Vegetative state.
4, therapeutic outcome:
Table 1: the preceding patient's of treatment ordinary circumstance
Table 2: the comparison of seminar and matched group
The basic cure rate 50% of oral liquid of the present invention, total effective rate 94.4%.The basic cure rate 45.1% of matched group, total effective rate 88.7%.
Four, the specific embodiment
Take by weighing medical material according to following proportioning:
Radix Astragali 600g Radix Salviae Miltiorrhizae 600g
Radix Angelicae Sinensis 300g Rhizoma Chuanxiong 150g
Radix Paeoniae Rubra 225g flower 150g
Pheretima 150g
Production method is as follows:
Get the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Flos Carthami and Pheretima Chinese crude drug, the water logging that adds 6 times of amounts was steeped 1 hour, then, decoct 2 times, each 1.5 hours, merge decoction liquor, be concentrated into 1: 2 (g/ml), add ethanol precipitation 2 times, make to contain alcohol amount and reach 75%, reclaim ethanol, add water to the about 1000ml of solution total amount again, add an amount of stevioside then, transfer PH to 6.0-7.5 with 40%NaOH, placed 24 hours, filter, sterilization, quantitative package.
Claims (3)
1, a kind of medicine for the treatment of the heart, cerebrovascular disease is characterized in that it is to be made by following materials of weight proportions medicine
The Radix Astragali 550-650g Radix Salviae Miltiorrhizae 550-650g
Radix Angelicae Sinensis 275-325g Rhizoma Chuanxiong 140-160g
Radix Paeoniae Rubra 200-250g Flos Carthami 140-160g
Pheretima 140-160g.
2, the medicine of the treatment heart according to claim 1, cerebrovascular disease, wherein the weight proportion of each crude drug is
Radix Astragali 600g Radix Salviae Miltiorrhizae 600g
Radix Angelicae Sinensis 300g Rhizoma Chuanxiong 150g
Radix Paeoniae Rubra 225g Flos Carthami 150g
Pheretima 150g.
3, the preparation method of the medicine of the claim 1 or the 2 described treatment hearts, cerebrovascular disease, it is characterized in that: get the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Flos Carthami and Pheretima Chinese crude drug, the water logging that adds 6 times of amounts was steeped 1 hour, then, decoct each 1.5 hours 2 times, merge decoction liquor, be concentrated into 1: 2g/ml, add ethanol precipitation 2 times, make to contain alcohol amount and reach 75%, reclaim ethanol, add water to the about 1000ml of solution total amount again, add an amount of stevioside then, transfer PH to 6.0-7.5 with 40%NaOH, placed 24 hours, filter sterilization, quantitative package.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100566320A CN100471508C (en) | 2005-04-05 | 2005-04-05 | Medicine for treating cardiac and cerebral vascular diseases and its prepn process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100566320A CN100471508C (en) | 2005-04-05 | 2005-04-05 | Medicine for treating cardiac and cerebral vascular diseases and its prepn process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1846737A CN1846737A (en) | 2006-10-18 |
| CN100471508C true CN100471508C (en) | 2009-03-25 |
Family
ID=37076618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100566320A Expired - Fee Related CN100471508C (en) | 2005-04-05 | 2005-04-05 | Medicine for treating cardiac and cerebral vascular diseases and its prepn process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100471508C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101461843B (en) * | 2009-01-13 | 2011-06-08 | 神威药业有限公司 | Medicament composition for ischemic disease and application thereof in medicinal preparation |
| CN104606513B (en) * | 2015-02-11 | 2018-06-08 | 青岛市市立医院 | A kind of Chinese medicine for treating cardiovascular and cerebrovascular disease and preparation method thereof |
| CN105497790A (en) * | 2015-12-28 | 2016-04-20 | 高春喜 | Medicine composition for preventing and treating cardiovascular and cerebrovascular infarction |
| CN105708922A (en) * | 2016-01-28 | 2016-06-29 | 李庆升 | Capsule capable of dissolving thrombus |
| CN110151883A (en) * | 2019-05-09 | 2019-08-23 | 李士月 | It is a kind of improve cardiovascular and cerebrovascular disease Chinese medicine external spray and its application |
| CN110353065A (en) * | 2019-08-12 | 2019-10-22 | 方杨泉 | A kind of cardiovascular and cerebrovascular takes care of health tea and preparation method thereof |
-
2005
- 2005-04-05 CN CNB2005100566320A patent/CN100471508C/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 中医在治疗高脂血症方面的进展. 张秀辉.继续医学教育，第16卷第5期. 2002 |
| 中医在治疗高脂血症方面的进展. 张秀辉.继续医学教育，第16卷第5期. 2002 * |
| 益气活血法在治疗老年病中的应用. 王华陆等.黑龙江医学，第28卷第6期. 2004 |
| 益气活血法在治疗老年病中的应用. 王华陆等.黑龙江医学，第28卷第6期. 2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1846737A (en) | 2006-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100471508C (en) | Medicine for treating cardiac and cerebral vascular diseases and its prepn process | |
| CN100376229C (en) | A medicinal wine for treating rheumatic and rheumatoid disease | |
| CN102512521A (en) | Traditional Chinese medicine composition for treating apoplexy sequela | |
| CN103301408B (en) | Traditional Chinese medicine extract and massage cream prepared from extract | |
| CN101284057A (en) | Yaotongning medicine and preparation method thereof | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN101229345B (en) | Qi-replenishing and blood-enriching medicine | |
| CN1310664C (en) | Chinese medicine capsule for treating cardiac and cerebral vascular diseases and its production process | |
| CN115581730A (en) | Traditional Chinese medicine composition for preventing and treating deep venous thrombosis and application thereof | |
| CN102198181B (en) | Antithrombotic and thrombosis-eliminating preparation | |
| CN1283485A (en) | Instant particles 'Xinnaotong' for treating heart and brain diseases | |
| CN1197597C (en) | Exterior Chinese medicine Oil-in-Water (O/W) type prescription for reduce swelling and ease pain and its preparing method | |
| CN113398211A (en) | Traditional Chinese medicine treatment method for cervical precancerous lesion | |
| CN102293985A (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN102614344B (en) | Traditional Chinese medicine for treating qi-blood deficiency periodontitis, preparation method and administration method thereof | |
| CN1672699A (en) | Medicine for treating phlebothrombosis and thrombotic superficial phlebitis of lower limb and its prepn | |
| CN104491324A (en) | Aerosol for postoperative patient to promote blood circulation and remove obstruction in channels | |
| CN1257739C (en) | Senshitong mixture for treating nephrolithiasis | |
| CN102641480A (en) | Traditional Chinese medicine composite used for treating microcirculation disturbance and preparation method thereof | |
| CN106176998A (en) | A kind of compositions for treating goat skin submental lymph nodes abscess | |
| CN104306734A (en) | Plaster preparation for external use for treating diabetic gangrene and preparation method thereof | |
| RU2571287C1 (en) | Agent for endoecological rehabilitation | |
| CN109646539A (en) | A kind of Chinese medicine composition and its preparation method and application improving local circulation obstacle | |
| CN117159633A (en) | Traditional Chinese medicine composition for treating isolated distal deep vein thrombosis, decoction and Chinese patent medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090325 Termination date: 20130405 |